Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation

Verastem Oncology Inc VSTM stock is trading higher after updated data from the ongoing Phase 1/2 FRAME study.
The investigator-sponsored study is investigating VS-6766, Verastem's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low-grade serous ovarian cancer (LGSOC).
Related Link: Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock.
The findings were presented at the European Society of Medical Oncology (ESMO21) Congress 2021.
In the study, the median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib is 23.0 months.
11 of 24 (46%) patients treated with the combination achieved a confirmed partial response (PR).
Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.
The Company said that for other therapies studied in recurrent LGSOC, response rates have been between 6% and 26%, and mPFS was between 7.2 and 13.0 months.
As of the April data cutoff date, 13 of 24 patients (54%) remained on study.
Verastem's Company-sponsored, registration-directed Phase 2 RAMP 201 study evaluating VS-6766 both alone and in combination with defactinib in patients with recurrent LGSOC is ongoing.
The Company plans to report top-line results from the selection portion of the study in 1H of 2022.
Price Action: VSTM shares are up 30.4% at $3.60 during the premarket session on the last check Monday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga